Literature DB >> 18362252

Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data.

Anna Bennet1, Emanuele Di Angelantonio, Sebhat Erqou, Gudny Eiriksdottir, Gunnar Sigurdsson, Mark Woodward, Ann Rumley, Gordon D O Lowe, John Danesh, Vilmundur Gudnason.   

Abstract

BACKGROUND: Large-scale prospective data are needed to determine whether associations between lipoprotein(a) (Lp[a]) and coronary heart disease (CHD) risk are independent of established risk factors, to characterize the shape of this relationship, and to quantify associations in relevant subgroups.
METHODS: Levels of Lp(a) were measured in samples obtained at baseline from 2047 patients who had first-ever nonfatal myocardial infarction or who died of CHD during the study and from 3921 control participants in the Reykjavik Study (n=18 569), as well as in paired samples obtained 12 years apart from 372 participants to quantify within-person fluctuations.
RESULTS: Baseline Lp(a) levels had little or no correlation with known cardiovascular risk factors, such as age, sex, total cholesterol level, and blood pressure. The Lp(a) values were highly consistent from decade to decade, with a regression dilution ratio (calculated on the log scale) of 0.92 (95% confidence interval, 0.85-0.99). The odds ratio for CHD, unaltered after adjustment for several established risk factors (age, sex, smoking status, blood pressure, total cholesterol, triglycerides level, diabetes mellitus, and body mass index), was 1.60 (95% confidence interval, 1.38-1.85) in a comparison of extreme thirds of baseline Lp(a) levels. Odds ratios were progressively higher with increasing Lp(a) levels and did not vary materially by several individual- or study-level characteristics.
CONCLUSIONS: There are independent, continuous associations between Lp(a) levels and risk of future CHD in a broad range of individuals. Levels of Lp(a) are highly stable within individuals across many years and are only weakly correlated with known risk factors. Further assessment of their possible role in CHD prevention is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362252     DOI: 10.1001/archinte.168.6.598

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  79 in total

1.  Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study).

Authors:  Stefano Volpato; Giovanni B Vigna; Mary M McDermott; Margherita Cavalieri; Cinzia Maraldi; Fulvio Lauretani; Stefania Bandinelli; Giovanni Zuliani; Jack M Guralnik; Renato Fellin; Luigi Ferrucci
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

2.  Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complications.

Authors:  Radhakrishnan Chandni; Kollengode Parameswaran Ramamoorthy
Journal:  World J Diabetes       Date:  2012-05-15

Review 3.  Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.

Authors:  Massimo Franchini; Enrico Capuzzo; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-12-22       Impact factor: 3.443

Review 4.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 5.  Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics.

Authors:  Christopher C Imes; Melissa A Austin
Journal:  Biol Res Nurs       Date:  2012-04-23       Impact factor: 2.522

Review 6.  Screening for and management of elevated Lp(a).

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

7.  Risk factors: Lipoprotein(a) and coronary disease-moving closer to causality.

Authors:  John Danesh; Sebhat Erqou
Journal:  Nat Rev Cardiol       Date:  2009-09       Impact factor: 32.419

Review 8.  Targeting lipoprotein (a): an evolving therapeutic landscape.

Authors:  Lillian C Man; Erik Kelly; Danielle Duffy
Journal:  Curr Atheroscler Rep       Date:  2015-05       Impact factor: 5.113

9.  Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort.

Authors:  Eric J Brandt; Arya Mani; Erica S Spatz; Nihar R Desai; Khurram Nasir
Journal:  J Clin Lipidol       Date:  2020-07-03       Impact factor: 4.766

10.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.

Authors:  Beate R Jaeger; Yvonne Richter; Dorothea Nagel; Franz Heigl; Anja Vogt; Eberhard Roeseler; Klaus Parhofer; Wolfgang Ramlow; Michael Koch; Gerd Utermann; Carlos A Labarrere; Dietrich Seidel
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.